# AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05211570** · PHASE1,PHASE2 · RECRUITING · sponsor: **AB Science** · enrollment: 78 (estimated)

## Conditions studied

- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- Myelodysplastic Syndrome Acute Myeloid Leukemia

## Interventions

- **DRUG:** AB8939
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05211570
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211570, "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05211570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*